Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028 ...

The funding, which brings GSK’s expenditure in US manufacturing capabilities close to $1.3bn, will establish a new vaccines drug substance facility and an R&D pilot plant.

After making a splash in the U.K. earlier this year, GSK is laying out plans for its biggest U.S. manufacturing investment yet. GSK is investing up to $800 million to double the size and capacity ...

Vaccine manufacturer GSK plans to invest $800 million in its Lancaster County facility, creating 200 new jobs and expanding its manufacturing and R&D capabilities.

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...